Medchemexpress

Network Version

CHR-6494 Data Sheet

Product Name: CHR-6494
CAS No.: 1333377-65-3
Cat. No.: HY-15217
MWt: 292.34
Formula: C16H16N6
Purity : >98%
Solubility: DMSO : 50 mg/mL (171.03 mM; Need ultrasonic)
Mechanisms: Target: Cancer
Biological Activity:
CHR-6494 is a potent inhibitor of haspin, with an IC50 of 2 nM. CHR-6494 inhibits histone H3T3 phosphorylation. CHR-6494 can be used in the research of cancer[1]. IC50 & Target: IC50: 2 nM (haspin)[1] In Vitro: CHR-6494 (0-10-5 nM; 72 hours) dose-dependently inhibits the growth of cancer cells, such as HCT-116, HeLa, MDA-MB-231, and Wi-38 cells, with IC50s of 500 nM, 473 nM, 752 nM and 1059 nM, respectively[1].
CHR-6494 (500 nM) produces a mitotic catastrophe with abnormal morphology of the mitotic spindle and centrosome amplification, and upregulates the spindle assembly checkpoint protein BUB1 and the marker of mitotic arrest cyclin B1[1].
CHR-6494 exhibits inhibitory activities against melanoma cell lines, including BRAFV600E mutants, NRAS mutants, and wild type cells, with IC50s ranging from 396 nM to 1229 nM[2].
CHR-6494 (300 nM and 600 nM; 72 hours) induces apoptosis, increases caspase 3/7 activity by 3- and 6-fold, respectively in COLO-792 cells, and to 8.5- and 16-fold in RPMI-7951 cells[2].
CHR-6494 in combination with MEK inhibitors synergistically inhibits viability of melanoma cells, enhances apoptosis in melanoma cells, modulates cell cycle progression independently by arresting melanoma cells at different phases, and suppresses migration of melanoma cells[2].
CHR-6494 (50, 200 nM; 1 week) enhances the antiproliferative effects of MLN8237 in MDA-MB-231, SKBR3 breast cancer cells[3].
CHR-6494 (200 nM; 72 hours) enhances the apoptosis of MDA-MB-231 and SKBR3 cells when combined with MLN8237[3]. In Vivo: CHR-6494 (50 mg/kg; i.p. in two cycles of five consecutive days for 15 days) inhibits the growth of tumor and cuases no obvious body weight change in nude mice bearing HCT-116 human colorectal cancer cells[1].
CHR-6494 (20 mg/kg; intraperitoneal injection for 15 consecutive days) inhibits the tumor volume and weight compared with the control group in nude mice bearing MDA-MB-231 xenograft tumors[3].
CHR-6494 (20 mg/kg; intraperitoneal injection for 15 consecutive days) enhances the tumor volume and weight inhibition of MLN8237 (20 mg/kg; p.o.) in vivo[3].

Caution: Not fully tested. For research purposes only

Medchemexpress LLC

www.medchemexpress.com

1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA

Tel: 609-228-6898 Fax: 609-228-5909 Email: [email protected] Web:www.medchemexpress.com

Keywords: buy CHR-6494 | CHR-6494 Supplier | purchase CHR-6494 | CHR-6494 cost | CHR-6494 manufacturer | order CHR-6494 | CHR-6494 distributor | CHR-6494 structure buy 1333377-65-3 | 1333377-65-3 Supplier | purchase 1333377-65-3 | 1333377-65-3 cost | 1333377-65-3 manufacturer | order 1333377-65-3 | 1333377-65-3 distributor | 1333377-65-3 structure